|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
AALP Apolipoprotein C3
Test Code37866
Preferred Specimen
Red Top

Patient Preparation
Patient should be fasting 10-12 hours
Minimum Volume
0.5 mL

Instructions
1. Collect and label sample according to standard protocols.
2. Gently invert tube 5 times immediately after draw. Do not shake.
3. Allow blood to clot for 30 minutes.
4. Centrifuge for 10 minutes.
5. Store serum at 2-8° C after collection and ship the same day.
2. Gently invert tube 5 times immediately after draw. Do not shake.
3. Allow blood to clot for 30 minutes.
4. Centrifuge for 10 minutes.
5. Store serum at 2-8° C after collection and ship the same day.
Transport Container
Transport tube
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: Unacceptable
Refrigerated: 21 days
Frozen: 21 days
Refrigerated: 21 days
Frozen: 21 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Lipemia
Methodology
Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
This test is not available for New York patient testing.
Setup Schedule
Every other day
Reference Range
| Male | 11.34-40.54 nmol/L |
| Female | 13.42-49.88 nmol/L |
Clinical Significance
ApoC3 has been reported to be tightly associated with triglyceride metabolism and coronary artery disease (CAD) susceptibility. HDL ApoC3 is elevated in CAD patients and inversely correlated with cholesterol efflux capacity [1]. Genetic epidemiological studies found that loss-of-function mutations in the ApoC3 gene is associated with reduced CAD risk and total ApoC3 is associated with increased risk for cardiovascular events [2,3]
References
1. Luo M, et al. 2017;7(1):2312. doi:10.1038/s41598-017- 02601-7
2. Crosby J, et al. 2014;371(1):22-31. doi:10.1056/NEJMoa 1307095
3. Jorgensen A, et al. 2014;371(1):32-41. doi:10.1056/NEJMoa 1308027
References
1. Luo M, et al. 2017;7(1):2312. doi:10.1038/s41598-017- 02601-7
2. Crosby J, et al. 2014;371(1):22-31. doi:10.1056/NEJMoa 1307095
3. Jorgensen A, et al. 2014;371(1):32-41. doi:10.1056/NEJMoa 1308027

